Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer
Open Access
- 31 July 2017
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 12 (11), 1733-1736
- https://doi.org/10.1016/j.jtho.2017.07.025
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialThe Lancet Oncology, 2017
- Can immunostimulatory agents enhance the abscopal effect of radiotherapy?European Journal Of Cancer, 2016
- Role of Local Radiation Therapy in Cancer ImmunotherapyJAMA Oncology, 2015
- Combination cancer immunotherapies tailored to the tumour microenvironmentNature Reviews Clinical Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabJournal of Clinical Oncology, 2015
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung CancerCancer Immunology Research, 2013
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012